Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

NCT ID: NCT06587503

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-31
• Study Completion Date: 2025-05-31

Brief Summary

Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases. This is a phase IV vaccine trial that looks to establish if two licenced vaccines, the rVSVΔG-ZEBOV-GP vaccine for protection against Ebola virus and messenger ribonucleic acid (mRNA) COVID vaccine for protection against SARS-CoV-2 virus, given concurrently to self selected healthy adult volunteers confers an acceptable safety profile and immunogenicity response.

Detailed Description

Vaccines for the prevention of severe disease caused by Ebola virus and SARS-CoV-2 virus are routinely offered to adults at higher risk of exposure in African settings. For protection from Ebola virus, the main target populations are epidemiologically-identified and include healthcare workers, refugees, and people living in outbreak zones. These target populations are also routinely offered vaccines for other vaccine-preventable diseases. However, there are currently no data on whether the co-administration of rVSVΔG-ZEBOV-GP with other vaccines has an acceptable profile of reactogenicity and antigen-specific immunogenicity, and concomitant use of rVSVΔG-ZEBOV-GP with other vaccines is not recommended. Clinical trial data on the co-administration of rVSVΔG-ZEBOV-GP with other vaccines prioritised for the same population, and especially in the context of a new era in mRNA vaccine technology, would have significant relevance to how protection to more than one disease can be provided at a single visit to a vaccination clinic. This, in turn, has the potential to improve vaccine coverage and improve the efficiency of vaccine policy and logistics, as well as being the first step evaluation in the evaluation of Vesicular stomatitis virus-vectored vaccine technology with lipid-enveloped mRNA platforms that are going to be increasingly used in other formulations against other/future infectious diseases targets.

There are no preliminary data in this first-of-kind study.

The advent of the SARS-CoV-2 virus and COVID-19 pandemic signalled the accelerated development of lipid-nanoparticle mRNA vaccine technology with great success. The mRNA platform is highly adaptable to new disease targets, including cancer and infectious diseases pathogens, and a multitude of vaccine candidates are currently in development for outstanding global health priorities that have eluded pre-pandemic technologies. However, there remains very little known about using mRNA technologies in combination with, or concurrent to, other vaccine technologies and whether there are any adverse signals associated with safety or antigen-specific immune response/protection. Earlier trials have focussed on using SARS-CoV-2 mRNA vaccines in combination with adjuvant-protein vaccines for seasonal influenza (and herpes-zoster virus, in setup) and have reported favourable safety and humoral immune responses that has resulted in recommended concurrent vaccine dose administration into the annual seasonal vaccination schedule of UK nationals. These study data have significantly supported public confidence in accepting two licenced vaccines at the same time and significant efficiency gains in vaccine coverage and public protection. The concurrent administration of mRNA vaccines with attenuated or replication-incompetent viral-vectored vaccines has not, to our knowledge, been assessed although many trials reported favourable safety and immunogenicity with heterologous combinations of these vaccine platforms for protection against COVID-19. Since existing mRNA COVID-19 vaccines and new mRNA constructs against other infectious diseases are expected to become routine immunisations for key members of the population, such as healthcare workers and older adults, research is needed to inform whether concurrent or co-administration with other vaccines are possible. For African populations, the risk of disease outbreaks from Ebola remains high and the future use of rVSVΔG-ZEBOV-GP is expected, along with other measures, to mitigate the risks to healthcare workers and the wider public. Assessing the safety and immunogenicity of rVSVΔG-ZEBOV-GP vaccine in the context of expected gains in public confidence and policy implementation with co-administration with mRNA vaccine technologies is a major subject of interest for African populations and preparedness for future disease outbreaks.

This is a single-centre, randomized, single-blinded, vaccine safety and immunogenicity study in healthy adults living in Rwanda. The EbolaCov trial aims to inform whether the Ebola vaccine rVSVΔG-ZEBOV-GP can be administered concurrent to a BioNTech - Pfizer COVID-19 booster dose without an unacceptable increase in reactogenicity and/or loss of humoral immunogenicity to Ebola vaccine antigen.

The investigators aim to primarily recruit participants who are current healthcare workers, although the study will be open all eligible members of the public. Participants of both genders aged 18-50 years who are in good health and who are able to provide written informed consent, will be eligible for inclusion in this study. The recruitment target is recruit 72 participants who will be randomised in a 1:1 ratio to one of two groups.

There will be four study visits over 6 months. Participants will be monitored for any reactions and other adverse events for 7 days after each immunisation via self reported e-diary, and for significant adverse events throughout the study.

The geometric mean titre (GMT) and antigen-specific antibody titre will be measured by glycoprotein-enzyme-linked immunosorbent assay at baseline, 28-days and 180-days after vaccination.

Conditions

Ebola Virus Disease; COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Placebo

Receive an intramuscular injection of a placebo concurrently with a dose of rVSV∆G-ZEBOV-GP vaccine

Group Type: PLACEBO_COMPARATOR

1mL saline solution

Intervention Type: BIOLOGICAL

Placebo

rVSV∆G-ZEBOV-GP

Intervention Type: BIOLOGICAL

Vaccine for protection from Zaire Ebola virus

Concurrent vaccination

Receive an intramuscular dose of BioNTech - Pfizer COVID-19 concurrently with a dose of rVSV∆G-ZEBOV-GP vaccine

Group Type: EXPERIMENTAL

BioNTech - Pfizer COVID-19 vaccine

Intervention Type: BIOLOGICAL

Vaccine for protection from COVID-19

rVSV∆G-ZEBOV-GP

Intervention Type: BIOLOGICAL

Vaccine for protection from Zaire Ebola virus

Interventions

BioNTech - Pfizer COVID-19 vaccine

Vaccine for protection from COVID-19

Intervention Type: BIOLOGICAL

1mL saline solution

Placebo

Intervention Type: BIOLOGICAL

rVSV∆G-ZEBOV-GP

Vaccine for protection from Zaire Ebola virus

Intervention Type: BIOLOGICAL

Other Intervention Names

Cominarty; rVSV∆G-ZEBOV-GP; Ervebo

Eligibility Criteria

Inclusion Criteria

• Healthy male and female adults between ages 18-50 years, who are able and willing to provide written informed consent and will comply with the study requirements.
• Already completed a primary course of COVID-19 immunisation (any World Health Organisation approved primary immunisation course is acceptable).

Exclusion Criteria

• Unwilling or unable to provide written informed consent to take part
• Unwilling or unable to comply with study procedures
• Previously received an Ebola vaccine or previous exposure to Ebola virus (including serological and clinical diagnoses, irrespective of viral strain)
• Not received a primary course of COVID-19 immunisation
• History of any suspected or confirmed disorder of the immune system that, in the opinion of the Investigators, might impair the results of the study
• Use of immunosuppressant medication within the past 6 months (excluding topical steroids or oral steroid courses lasting <7 days)
• Current diagnosis or treatment of cancer (unless non-melanomatous skin cancer)
• Have a bleeding disorder deemed significant by study doctor
• Pregnant or breast-feeding females
• Able to avoid close contact with vulnerable individuals, including via high-risk blood and bodily fluids for 6 weeks following vaccination to reduce the risk of transmission to vulnerable individuals (e.g. immuno-compromised individuals, individuals receiving immunosuppressive therapy, pregnant or breast-feeding women, children <1 year of age).
• Unable to prevent contact of their blood or bodily fluids with farm animals in the 6 weeks following vaccination
• Plan to donate blood in the 6 weeks following vaccination
• Hypersensitivity to any active substances, excipients, or rice protein.
• History of anaphylaxis to any component of vaccine formulation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Project San Francisco

UNKNOWN

Sponsor Role: collaborator

Rwanda Biomedical Centre

OTHER

Sponsor Role: collaborator

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

University of Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Christopher Green, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Birmingham

Central Contacts

Julien Nyombayire, MD, MSc

Role: CONTACT

jnyombayire@rzhrg-mail.org

+250 252 503 233

References

Gokani K, Taylor A, Packham A, Musabyimana JP, Shema H, Mutabaruka A, Roche S, Takwoingi Y, Umuhoza C, Nyombayire J, Muvunyi C, Green C. Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults (EbolaCov): protocol for a phase IV, single-centre, single-blinded, randomised controlled trial. BMJ Open. 2025 Sep 21;15(9):e102898. doi: 10.1136/bmjopen-2025-102898.

Reference Type: DERIVED

PMID: 40976661 (View on PubMed)

Other Identifiers

PACTR202407764378004

Identifier Type: REGISTRY

Identifier Source: secondary_id

EbolaCov

Identifier Type: -

Identifier Source: org_study_id